Latest News

Coronavirus Breakthrough: Senhwa Reports First eIND Silmitasertib Treated Severe COVID-19 Patient - Discharged Following Five Days of Treatment

Sep

11

2020

Senhwa Biosciences’s Silmitasertib Receives Rare Pediatric Disease Designation from U.S. FDA for Treatment of Recurrent Sonic Hedgehog Medulloblastoma

Jul

06

2020

Coronavirus Breakthrough: New Study Highlights Senhwa Biosciences Silmitasertib as Potential Treatment for COVID-19

Jul

02

2020

Senhwa’s Abstract of Silmitasertib for the Treatment of Basal Cell Carcinoma Clinical Trial Accepted for 2020 ASCO Online Publication

May

14

2020

Senhwa Biosciences Silmitasertib Named as Potential Covid-19 Therapy

Mar

31

2020

Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid Tumors at 2019 SABCS

Dec

13

2019

Senhwa Biosciences Silmitasertib / Medulloblastoma Trial Completed 1st Patient Enrollment

Jul

25

2019

Inhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian Cancer

May

02

2019